» Articles » PMID: 35328721

Increasing Role of Targeted Immunotherapies in the Treatment of AML

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Mar 25
PMID 35328721
Authors
Affiliations
Soon will be listed here.
Abstract

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. The standard of care in medically and physically fit patients is intensive induction therapy. The majority of these intensively treated patients achieve a complete remission. However, a high number of these patients will experience relapse. In patients older than 60 years, the results are even worse. Therefore, new therapeutic approaches are desperately needed. One promising approach in high-risk leukemia to prevent relapse is the induction of the immune system simultaneously or after reduction of the initial tumor burden. Different immunotherapeutic approaches such as allogenic stem cell transplantation or donor lymphocyte infusions are already standard therapies, but other options for AML treatment are in the pipeline. Moreover, the therapeutic landscape in AML is rapidly changing, and in the last years, a number of immunogenic targets structures eligible for specific therapy, risk assessment or evaluation of disease course were determined. For example, leukemia-associated antigens (LAA) showed to be critical as biomarkers of disease state and survival, as well as markers of minimal residual disease (MRD). Yet many mechanisms and properties are still insufficiently understood, which also represents a great potential for this form of therapy. Therefore, targeted therapy as immunotherapy could turn into an efficient tool to clear residual disease, improve the outcome of AML patients and reduce the relapse risk. In this review, established but also emerging immunotherapeutic approaches for AML patients will be discussed.

Citing Articles

A Nomogram Built on Clinical Factors and CT Attenuation Scores for Predicting Treatment Response of Acute Myeloid Leukemia Patients.

Liu L, Lu W, Xiong L, Qi H, Gale R, Yin B Biomedicines. 2025; 13(1).

PMID: 39857781 PMC: 11763309. DOI: 10.3390/biomedicines13010198.


Bispecific antibody (ABL602 2 + 1) induced bistable acute myeloid leukemia kinetics.

Xu S Sci Rep. 2024; 14(1):25557.

PMID: 39462141 PMC: 11513055. DOI: 10.1038/s41598-024-75971-4.


Analysis of action of 1,4-naphthoquinone scaffold-derived compounds against acute myeloid leukemia based on network pharmacology, molecular docking and molecular dynamics simulation.

Chen R, Liu H, Meng W, Sun J Sci Rep. 2024; 14(1):21043.

PMID: 39251712 PMC: 11385794. DOI: 10.1038/s41598-024-70937-y.


Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release.

Lee E, Lee S, Park S, Son Y, Yoo J, Koh Y J Immunother Cancer. 2023; 11(10).

PMID: 37848261 PMC: 10582864. DOI: 10.1136/jitc-2023-007494.


Divergent CD4 T-cell profiles are associated with anti-HLA alloimmunization status in platelet-transfused AML patients.

Khelfa M, Leclerc M, Kerbrat S, Boudjemai Y, Benchouaia M, Neyrinck-Leglantier D Front Immunol. 2023; 14:1165973.

PMID: 37701444 PMC: 10493329. DOI: 10.3389/fimmu.2023.1165973.


References
1.
Jetani H, Garcia-Cadenas I, Nerreter T, Thomas S, Rydzek J, Briones Meijide J . CAR T-cells targeting FLT3 have potent activity against FLT3ITD AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia. 2018; 32(5):1168-1179. DOI: 10.1038/s41375-018-0009-0. View

2.
Riether C, Pabst T, Hopner S, Bacher U, Hinterbrandner M, Banz Y . Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020; 26(9):1459-1467. DOI: 10.1038/s41591-020-0910-8. View

3.
Dohner H, Wei A, Lowenberg B . Towards precision medicine for AML. Nat Rev Clin Oncol. 2021; 18(9):577-590. DOI: 10.1038/s41571-021-00509-w. View

4.
Cortes J, Dombret H, Merchant A, Tauchi T, DiRienzo C, Sleight B . Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. Future Oncol. 2019; 15(31):3531-3545. DOI: 10.2217/fon-2019-0373. View

5.
Daver N, Schlenk R, Russell N, Levis M . Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019; 33(2):299-312. PMC: 6365380. DOI: 10.1038/s41375-018-0357-9. View